ONCO3 Share Price Performance
R$0
-4.65 (-100.00%)
Price R$0
Fair ValueR$2.48
Share Pricen/a
Narrative Update • Jun 22
Oncoclínicas do Brasil Serviços Médicos S.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
ONCO3 Community Narratives
AN
Fair Value
·Fair Value R$2.48 45.6% undervalued intrinsic discount
Debt Reduction And Revenue Diversification Will Secure Future Stability
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value R$0.7 92.9% overvalued intrinsic discount
Brazil's Tightening Policies And High Costs Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value R$3.5 61.4% undervalued intrinsic discount
Brazil's Aging Demographics And Digital Health Will Expand Oncology Care
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Debt Reduction And Revenue Diversification Will Secure Future Stability
Oncoclínicas is trying to turn the page by paying down debt, cutting reliance on a single big customer, and signing new partnerships to bring in steadier business. The big question is whether these cost cuts and deal-driven growth can overcome recent write-downs, weaker profitability, and the strain of heavy borrowing.Read more
AN
R$2.48
45.6% undervalued intrinsic discount
Fair Value
Profit Margin
8.67%
Future PE
10.29x
Price in 2029
R$4.54
Brazil's Tightening Policies And High Costs Will Erode Margins
Brazil’s cancer care group Oncoclínicas faces growing pressure as regulators, inflation, and insurers push for treatment that’s paid for based on results rather than volume. Add rising tech and expansion costs, and the story becomes whether recent debt cuts, new partnerships, and a leaner cost base can offset a tougher pricing environment.Read more
AN
R$0.7
92.9% overvalued intrinsic discount
Fair Value
Profit Margin
3.06%
Future PE
9.99x
Price in 2029
R$1.29
Brazil's Aging Demographics And Digital Health Will Expand Oncology Care
Brazil’s aging population is driving more demand for cancer care, and Oncoclínicas is positioning itself to catch that wave through new treatment centers, partnerships with big health plans, and more digital care. The catch is that tougher pricing rules, heavier competition, and rising costs could squeeze profits just as the company leans on growth and debt.Read more
AN
R$3.5
61.4% undervalued intrinsic discount
Fair Value
Profit Margin
2.47%
Future PE
54.22x
Price in 2029
R$6.47
Trending Discussion
Recently Updated Narratives
AN
ONCO3: 2026 Extraordinary Meetings Will Support Constructive Upside Outlook
Fair Value: R$2.48 45.6% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ONCO3: Higher Discount Rate And Lower P/E Will Likely Cap Upside
Fair Value: R$0.7 92.9% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ONCO3: Upcoming Shareholder Meetings Will Shape Bullish Repricing Potential
Fair Value: R$3.5 61.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Oncoclínicas do Brasil Serviços Médicos S.A. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
- -3.44
- 29.10%
- -71.05%
- 536.5%
About ONCO3
- Founded
- 2010
- Employees
- n/a
- CEO
- WebsiteView website
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, oral chemotherapy, and prostate cancer hormone therapy; and surgery procedures, such as breast, head and neck, lung, prostate cancer, stomach, bladder cancer, oncological, kidney cancer, gynecological, and testicular cancer. It also provides diagnostics services comprising pathological analysis, genetic testing, molecular journey, personalized medicine and individualized treatment, myelogram-bone marrow biopsy, and ONCO test-PDO. In addition, the company offers treatment support services, which include veinviewer, cryotherapy, integrative medicine, and DeLife, as well as hilotherapy, laser therapy, OC care line, OC precision medicine, OncoACCESS, survivorship, and telemedicine services. Oncoclínicas do Brasil Serviços Médicos S.A. was incorporated in 2010 and is headquartered in São Paulo, Brazil.
Recent ONCO3 News & Updates
Narrative Update • Jun 04
